glp-1 trial results today Efficacy and safety of a novel dual GIP and receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 Summary of the primary end-point

The GLP-1 landscape is expanding rapidly, and understanding the competitive context helps frame the retatrutide versus Mounjaro comparison

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

Documentation is mandatory: Provide your current A1C ( 6.4%), historical A1Cs proving you never hit 6.5%, a complete med list with start dates and dose changes and proof you completed all observation periods without adverse effects

This makes it particularly effective for individuals with type 2 diabetes who may also need help managing blood sugar levels while losing weight

If you always struggle with Friday injections during summer travel season, maybe Tuesday is a better permanent choice year-round